Cerecor raises $26M in a downsized IPO to fund its depression pipeline

Baltimore biotech Cerecor ($CERCU) raised $26 million in an IPO to bankroll its work on treatments for depression, issuing warrants to bring in the cash it needs. Cerecor priced 4 million units at $6.50 apiece, with each unit including one share of common stock, one warrant to purchase another share and a second warrant redeemable for a half share. With the proceeds, Cerecor is advancing three therapies for major depressive disorder, with two in Phase II and another in preclinical development. Release

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.